AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06716203 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Drug: Placebo Administered SC
Description: Drug: Placebo Administered SC
Study NCT06716450 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Multiplo TP/HIV Antibody Test
Description: The Multiplo TP/HIV Antibody Test (MedMira Laboratories Inc., Halifax, NS), \[Multiplo TP/HIV Test\] is a single use, rapid, vertical-flow in vitro qualitative immunoassay for the detection of antibodies to Human Immunodeficiency Virus (HIV) Type 1/Type 2 and Treponema pallidum (Syphilis) in human fingerstick blood. The Multiplo® TP/HIV Test is intended as an aid in the diagnosis of HIV1/2 and Syphilis infections in patients with signs and symptoms of HIV and syphilis. The test is intended for use by trained personnel in medical facilities, clinical laboratories, emergency care situations, and physicians' offices as an in vitro diagnostic device capable of providing results in less than five minutes. The Multiplo TP/HIV Test has not yet sought approval for self-testing. All required pre and post-test counselling guidelines must be followed in each setting in which the Multiplo TP/HIV Test is used. Results are read visually.
Study NCT06717009 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Preoperative three-dimensional reconstruction
Description: On the basis of conventional CT/MRI, the patient will undergo 3D reconstruction within 48 hours before surgery. The surgeon/researcher will conduct surgical planning according to the results of the 3D reconstruction and perform robot-assisted laparoscopic nephron sparing surgery.
Study NCT06095960 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telehealth MOM
Description: Patients will receive enhanced standard of care plus remote blood pressure monitoring, remote thermometer, and a 10- to 14-day post-partum telehealth visit.
Study NCT06095960 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Standard of Care
Description: Patients will receive enhanced standard of care which includes: education on symptoms and when to call their healthcare provider, comprehensive 6-week post-partum visit, and any healthcare deemed necessary by providers.
Study NCT06441461 — intervention group
Intervention type: OTHER
Intervention: Primary informal caregiver at work.
Description: Employees becoming a primary informal caregiver for a child or an adolescent with mental health problems in the period from 2000 to 2018.
Study NCT05861635 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Disitamab Vedotin combined with Tislelizumab
Description: Subjects who meet the requirements of the protocol will receive neoadjuvant treatment, and the specific administration arrangement is as follows:~Disitamab Vedotin, 2 mg/Kg, q2W, 8cycle Tislelizumab, 200mg, iv, q3W, 6cycle
Study NCT05121025 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Analysis of gut microbiome and immune signatures
Description: The investigators will analyse the microbiome composition (16S rDNA-sequencing and metagenomics), microbiome activity (RNA-sequencing of stool bacteria and metabolite sampling) and immune cell activity (leukocyte RNA-sequencing) of all study groups.
Study NCT05178784 — intervention group
Intervention type: DEVICE
Intervention: External Combined Occipital and Trigeminal Nerve Stimulation (eCOT-NS) stimulation
Description: Relivion®DP is a device by Neurolief that delivers external, combined Occipital and Trigeminal Nerve Stimulation (eCOT-NS), which is proposed as a novel treatment approach for MDD. The Relivion®DP device is designed for at-home self-administration by patients; it is comprised of a headset that holds electrodes, and it is worn externally on a person's head. When activated, the device delivers mild electrical stimulation pulses which can be managed by the user. The stimulation is intended to reduce MDD symptoms.
Study NCT05155033 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 200 mg IV over approximately 30 minutes on Day 1 of cycles 1 and 2 during Courses 1 and 2.
Study NCT05155033 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: Aldesleukin (IL-2) administration \[600,000 IU/kg IV bolus every 8 hours continuing for up to 4 days (maximum 10 doses)\] starting on Day 1 of cycles 1 and 2 during Course 1.
Study NCT06114719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Silymarin
Description: Subjects of the experimental group will receive silymarin (capsules containing 100 mg silymarin, expressed as silibinin) three days preoperatively. The dose they receive will be the recommended dose for the registered indications (400 mg daily, orally, divided into two doses).
Study NCT05639881 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhancing Your Immune Health
Description: In addition to routine mental health care, subjects receive an intervention to improve their immune health literacy and self-management behaviors.
Study NCT05639881 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhancing Your Immune Health
Description: In addition to routine mental health care, subjects receive an intervention to improve their immune health literacy and self-management behaviors.
Study NCT06032390 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AI assisted mammography screening interpretation
Description: Screening examinations will be analyzed by the AI system (Transpara, ScreenPoint Medical, Nijmegen, The Netherlands) that assigns each examination a cancer risk score 1-10. Examinations with a score 1-7 will be single read and examinations with score 8-10 will be double read. Examinations selected by one or two readers will be discussed in a consensus meeting. Examinations with an AI score of >9.8 will be selected for the consensus meeting by default. AI risk scores and image markings are provided to the readers only in the consensus meetings. The readers will decide whether to recall the woman for further assessment in consensus (standard procedure).
Study NCT06032390 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard mammography screening interpretation
Description: Screening examinations will be assessed according to standard of care: independently double read, examinations selected by one or two readers will be discussed in a consensus meeting, and the radiologists will decide whether to recall the woman for further assessment. Screening examinations will be analyzed by the AI system retrospectively but the results will not be made available to the radiologist, only used for comparison to the intervention group in results analyses.
Study NCT04972838 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Remaking Recess (RR)
Description: Remaking Recess is a flexible, school-based social engagement intervention for students with autism and their peers. The research team will work with school personnel to deliver RR during recess. RR is tailored based on the needs of schools, students, and staff.
Study NCT04972838 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Remaking Recess (RR)
Description: Remaking Recess is a flexible, school-based social engagement intervention for students with autism and their peers. The research team will work with school personnel to deliver RR during recess. RR is tailored based on the needs of schools, students, and staff.
Study NCT06433700 — intervention group
Intervention type: OTHER
Intervention: BAS
Description: NOMESCO (Nordic Medico-Statistical Committee) Classification of Surgical Procedures (KJDF10 \& KJDF11 \[gastric bypass\]; KJDF20 \& KJDF21 \[gastric banding\]; KJDF40, KJDF41, KJDF96 \& KJDF97 \[gastric sleeve\]).
Study NCT06433700 — intervention group
Intervention type: OTHER
Intervention: Non-BAS
Description: Patients without BAS codes
Study NCT06289465 — intervention group
Intervention type: OTHER
Intervention: Observation
Description: Seasonal workers will be assessed in the assessment area established in the hazelnut field and healthy controls will be assessed in their homes.
Study NCT05949879 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pecan LOW
Description: Participants are provided with a quantity of pecans that delivers 6% of the participant's estimated energy needs for 28 days.
Study NCT05949879 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pecan MID
Description: Participants are provided with a quantity of pecans that delivers 13% of the participant's estimated energy needs for 28 days.
Study NCT05949879 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pecan HIGH
Description: Participants are provided with a quantity of pecans that delivers 20% of the participant's estimated energy needs for 28 days.
Study NCT05949879 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CONTROL
Description: Participants are asked to maintain their current habitual diet and to avoid any tree nut/peanut consumption for the entire 28-day intervention period.
Study NCT06194578 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sterile Saline
Description: Sterile saline will be administered subcutaneously.
Study NCT05962944 — intervention group
Intervention type: DEVICE
Intervention: Olympus Cellsens software
Description: Olympus cellsens software will be used to visualise the cells and MS teams screen share will be used to send the live images in real time.
Study NCT06255405 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-compassion
Description: The dyadic parent-child self-compassion program is designed by the research team and validated by a panel of experts. It includes 5 weekly sessions. Each session lasts for 60 minutes. The dyads will be guided to do self-compassion practices (e.g. affectionate breathing, compassionate letters to oneself etc). Didactic topics, inquiry, and home practices are also involved.
Study NCT04893863 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard dressing
Description: Topical antibiotic ointment (Polysporin™ or formulary equivalent) and non-adherent petrolatum fine-meshed gauze (ADAPTIC™) applied every Monday, Wednesday and Friday (or equivalent).
Study NCT04893863 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PluroGel
Description: A 0.5 cm layer of PluroGel® followed by the above standard dressing. In addition, this will be covered with moistened gauze, kept moist twice daily. (The additional factors are the use of PluroGel® and moistened gauze. Standard dressing will continue to be used.)
Study NCT05373485 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVID-19 mRNA vaccine
Description: 2 doses of vaccine on Day 0 and Day 21
Study NCT05108610 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Shi-style manipulations
Description: Shi-style cervical manipulation is a spinal manipulation for cervical radiculopathy.It is a kind of traditional chinese massage and can dredge the meridian.Patients are treated every day for 30 minutes.Seven times at one course and totally there are two courses.3 times a week, once the other day（except the weekends）,30 minutes, 2 weeks.
Study NCT05108610 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cervical Traction control
Description: 6kg to 10kg, 3 times a week, once the other day（except the weekends）,20 minutes, 2 weeks.
Study NCT05078580 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iptacopan
Description: Single oral dose of iptacopan 200 mg oral capsules
Study NCT05373485 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 doses of placebo on Day 0 and Day 21
Study NCT05710887 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitrous oxide gas for inhalation
Description: Administration of inhaled 50% nitrous oxide in oxygen (FiO2 0.5) will be under the direct supervision of a licensed practitioner who is experienced in the use and administration of the study drug, and is familiar with the indications, effects, dosages, methods, and frequency and duration of administration, and with the hazards, contraindications, and side effects and the precautions to be taken (MD, or CRNA); with study patient monitoring of pulse oximetry, heart rate, respiratory, non-invasive blood pressure, and end-tidal carbon dioxide.
Study NCT05710887 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administration of the placebo (oxygen-air mixture \[FiO2 ≈0.3\]), will be under the direct supervision of a licensed practitioner who is experienced in the use and administration of the study drug, and is familiar with the indications, effects, dosages, methods, and frequency and duration of administration, and with the hazards, contraindications, and side effects and the precautions to be taken (MD, or CRNA); with study patient monitoring of pulse oximetry, heart rate, respiratory, non-invasive blood pressure, and end-tidal carbon dioxide.
Study NCT06068504 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Arm-cranking exercise
Description: Arm-cranking exercise
Study NCT06068504 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Heating
Description: Immersion of the foot in warm water
Study NCT06405386 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ReCharge
Description: ReCharge is an emotions-focused intervention that utilizes core components of Acceptance and Commitment Therapy (ACT) to address and minimize diabetes distress. This 5-week, group-based, virtual intervention will include a stepwise process to address diabetes distress and provide opportunities to practice new skills. Weekly assignments between the sessions will reinforce class material and give additional practice opportunities. Participants will be expected to interact in each session and will have opportunities to share their experiences and be engaged in discussion with the group and the facilitator.
Study NCT06405386 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TakeCharge
Description: TakeCharge is a problem-solving focused intervention that empowers participants to identify and make meaningful changes in their blood glucose management and other diabetes-related behaviors. This 5-week, group-based, virtual intervention will include a stepwise process to analyze data and resolve challenging situations surrounding diabetes management and provide opportunities to practice new skills. Weekly assignments between the sessions will reinforce class material and give additional practice opportunities. Participants will be expected to interact in each session and will have opportunities to share their experiences and be engaged in discussion with the group and the facilitator.
Study NCT06632782 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breath Awareness using pyramid
Description: Participants are provided 1-2 hr training for 6 weeks on bringing breath awareness to the present moment using a pyramid
Study NCT05481736 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Psilocybin
Description: COMP360 Psilocybin administered under supportive conditions
Study NCT05481736 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin
Description: COMP360 Psilocybin administered under supportive conditions
Study NCT05078580 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iptacopan
Description: Single oral dose of Iptacopan 200 mg oral capsules
Study NCT04781582 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lung volume reduction surgery
Description: Surgical lung volume reduction
Study NCT04781582 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bronchoscopic lung volume reduction
Description: Bronchoscopic lung volume reduction by endobronchial valves
Study NCT05155982 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVAC-1
Description: Intramuscular vaccine against SARS-CoV-2
Study NCT05155982 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Saline Placebo
Description: Intramuscular injection of saline placebo
Study NCT06505174 — intervention group
Intervention type: OTHER
Intervention: Hydroxypropyl Guar-based artificial tears four times per day
Description: Use of hydroxypropyl Guar-based artificial tears four times per day
Study NCT06276283 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DZD9008 plus Bevacizumab
Description: DZD9008, 200 mg or 300 mg, once daily plus Bevacizumab 15 mg/kg, once every 3 weeks
Study NCT05911529 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing
Description: In our study intervention, patients should receive four session of motivational interviewing (MI). Throughout the MI sessions, interviewers use common MI techniques including open-ended questions, affirmations, reflections, summaries, asking permission, expressing empathy, supporting self-efficacy, etc. Interviewers are clinical psychologists who received MI training immediately prior to the study.
Study NCT06430710 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intrusion
Description: 2 different methods for incisor intrusion
Study NCT06225557 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ERAS community recommendation
Description: Enhanced recovery techniques including opioid sparing anesthesia in elective cesarean section
Study NCT06225557 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional postoperative care
Description: Usual anesthesia and analgesia in elective cesarean section.
Study NCT05231993 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conization
Description: A cone biopsy to remove abnormal tissue.
Study NCT05231993 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Colposcopy
Description: 1. Colposcopy with biopsy within 3 months,endocervical sample, ultrasound and endometrial biopsy if the woman is ≥40~2. Colposcopy after 12 months if the first colposcopy and biopsies are normal~3. Cytology and HPV testing at 12 and 24 months if the second colposcopy is normal
Study NCT06486909 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Cerebrospinal Fluid (CSF) Sample
Description: Samples for glucose in CSF will be taken upon EVD/LD placement until EVD/LD removal (within the first 14 days).
Study NCT06486909 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood Serum Sample
Description: Samples for glucose in blood serum will be completed every day, for the first 14 days.
Study NCT05330975 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: 0.9% sodium chloride (normal saline) injection
Study NCT05330975 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.9% sodium chloride (normal saline) injection
Study NCT04686019 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Inspiratory muscle training (IMT)
Description: IMT and conventional neurorehabilitation - treatment as usual. The intervention group will add-on IMT sessions exercising at 30 % of MIP. MIP is measured by instructing the patient to perform five forceful inspirations against an occluded mouthpiece (Power Breath). The best score is multiplied by 0.3 to determine the resistance. IMT is performed with IMT Threshold flute with the calculated resistance. During the measurement with Power Breath the patient sits straight up and uses nose clip. The patient can receive help to hold the Power Breath if necessary.~One session of IMT with IMT threshold flute consists of 2 times 15 inspirations in normal breathing rhythm (5-10 min). Patients in the intervention group perform 2 sessions a day (morning and evening), training is performed prior to a meal, 7 days a week for 3 weeks.
Study NCT04569448 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brexpiprazole
Description: Adjunctive variable dose (1-3 mg/day) Brexpiprazole
Study NCT04796636 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Ascorbate
Description: As previously described
Study NCT06412588 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vonoprazan+amoxicillin+doxycycline+bismuth for 14 days
Description: Group A:The patient was treated with oral Vonoprazan 20 mg, bid + amoxicillin 1.0 g, bid + doxycycline 0.1 g, bid + bismuth for 14 days.
Study NCT06412588 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vonoprazan+Amoxicillin
Description: Group B: Patients were treated with oral Vonoprazan 20mg, bid + amoxicillin 1.0g, bid for 14 days.
Study NCT06412588 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vonoprazan+doxycycline
Description: Group C: Patients were treated with oral Vonoprazan 20 mg, bid + doxycycline 0.1 g, bid for 14 days.
Study NCT05330975 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1345
Description: Sterile liquid for injection
Study NCT05330975 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Afluria® Quadrivalent
Description: single-dose, pre-filled syringe for injection
Study NCT05330975 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Afluria® Quadrivalent
Description: single-dose, pre-filled syringe for injection
Study NCT05330975 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: mRNA-1273.214
Description: Sterile liquid for injection
Study NCT05330975 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1273.214
Description: Sterile liquid for injection
Study NCT05017623 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH003
Description: All subject will receive YH003 intravenously as single agent every three weeks (Q3W) for up to 1 years, until intolerable toxicity, confirmed disease progression, withdrawal of consent, or Investigator decision, whichever comes first.
Study NCT04286178 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: creatine monohydrate
Description: Creatine will be taken at a dose of 150mg/kg/day of creatine base divided into 2 daily doses up to 39.7kg in body weight, after which dosing will be based on body surface area (BSA) at 4.69g/m2/day. Creatine will be administered orally as a chewable tablet provided by BioTechUSA™. Tablets are 2g and contain 0.9g of creatine monohydrate which is equivalent to 0.8g of creatine base.